BJDX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

BJDX ▲ +179.07% at T+20d

NEUTRAL call ✓ call won +179.07% · α vs SPY +179.05% · entry $1.72 → $4.80

Next anchor: T+60d in 8w

Last close $5.23 (close Jun 8) · +204.07% from $1.72 entry

Entry anchored
May 7, 12:31 PM ET
via Databento tick

T+1d

+2.33%

call +2.33% · α +2.09%

$1.76

settled 5w ago

T+5d

+1.45%

call +1.45% · α -0.01%

$1.75

settled 27d ago

T+20d

+179.07%

call +179.07% · α +179.05%

$4.80

settled 5d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Bluejay Diagnostics provided a Q1 2026 corporate update highlighting continued enrollment in its SYMON-II pivotal study and manufacturing progress with Sanyoseiko. Financial results show a net loss of ~$1.9M and cash of $3.7M, consistent with prior quarters and pre-revenue stage. No material financial catalysts were announced.

Actionable Insight

Monitor SYMON-II completion and subsequent FDA 510(k) submission as key catalysts. Cash runway limited (~$3.7M) suggests potential need for financing within ~2 quarters.

Key Facts

SYMON-II pivotal study enrollment at ~680 of 750 target patients as of May 5, 2026
Cash and cash equivalents of ~$3.7M as of March 31, 2026
Net loss of ~$1.9M for Q1 2026, flat vs Q1 2025
Technical issues resolved with Symphony cartridge manufacturing; advancing toward analytical and clinical validation
No revenue reported; company remains pre-revenue

Financial Impact

No material financial impact; net loss unchanged at ~$1.9M, cash burn continues

net losscash position

Risk Factors

Cash runway may be insufficient to complete regulatory and clinical milestones without additional financing
Regulatory clearance for Symphony IL-6 test is uncertain and subject to FDA review
No revenue; stock relies on binary clinical/regulatory events

Market Snapshot

Exchange

Nasdaq

Sector

Surgical & Medical Instruments & Apparatus

Analyst Consensus

0% bullish (6 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3290498

9 reports for BJDX

T+1T+5T+20T+60

33% Hit rate 1 of 3 directional calls best @ T+5▲ +14.33%May 18, 2026

Filters

Reports for BJDX — sortable, filterable
	Type				Now
Jun 9, 2026 today	8-K NEUTRAL ★ 4/10	$4.53 awaiting T+1	awaiting T+1	—	$5.23 (+15.45%)
Jun 8, 2026 1d ago	8-K BEARISH ★ 7/10	$5.30 awaiting T+1	awaiting T+1	—	$5.23 (+1.32%)
Jun 6, 2026 4d ago	Press Release BEARISH ★ 7/10	$5.26 awaiting T+1	awaiting T+1	—	$5.23 (+0.57%)
Jun 2, 2026 7d ago	Press Release BEARISH ★ 5/10	$4.34 $4.51	▼ −3.92%	▼ −4.61%	$5.23 (−20.51%)
Jun 2, 2026 7d ago	PRESS-RELEASE / 8-K NEUTRAL ★ 4/10	$4.34 $4.51	▲ +3.92%	▲ +4.61%	$5.23 (+20.51%)
May 18, 2026 22d ago	Insider Cluster BULLISH ★ 7/10	$1.71 $1.78	▲ +3.98%	▲ +2.94%	$5.23 (+205.85%)
May 7, 2026 4w ago	8-K NEUTRAL ★ 3/10	$1.72 $1.76	▲ +2.33%	▲ +2.09%	$5.23 (+204.07%)
May 7, 2026 4w ago	Press Release NEUTRAL ★ 2/10	$1.72 $1.76	▲ +2.33%	▲ +2.09%	$5.23 (+204.07%)
Apr 7, 2026 9w ago	8-K BULLISH ★ 6/10	$2.05 $2.05	· 0.00%	▼ −2.54%	$5.23 (+155.12%)

US Market Status

Market Closed — Opens in 8h 35m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access